A detailed history of Met Life Investment Management, LLC transactions in Maxcyte, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 60,983 shares of MXCT stock, worth $258,567. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,983
Previous 60,983 -0.0%
Holding current value
$258,567
Previous $239,000 0.84%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.63 - $5.0 $48,333 - $66,575
13,315 Added 27.93%
60,983 $239,000
Q1 2024

May 14, 2024

BUY
$3.94 - $5.38 $187,811 - $256,453
47,668 New
47,668 $199,000
Q3 2023

May 09, 2024

SELL
$3.02 - $5.1 $25,537 - $43,125
-8,456 Reduced 15.07%
47,668 $148,000
Q2 2023

Apr 29, 2024

BUY
$3.69 - $5.35 $175,894 - $255,023
47,668 New
47,668 $218,000
Q2 2023

Aug 10, 2023

SELL
$3.69 - $5.35 $31,202 - $45,239
-8,456 Reduced 15.07%
47,668 $218,000
Q1 2023

May 09, 2024

BUY
$4.03 - $5.89 $226,179 - $330,570
56,124 New
56,124 $278 Million
Q1 2022

May 10, 2024

BUY
$5.26 - $10.84 $295,212 - $608,384
56,124 New
56,124 $392,000
Q1 2022

Mar 22, 2023

BUY
$5.26 - $10.84 $105,263 - $216,930
20,012 Added 55.42%
56,124 $392,000
Q1 2022

May 12, 2022

BUY
$5.26 - $10.84 $105,263 - $216,930
20,012 Added 55.42%
56,124 $392,000
Q4 2021

May 17, 2024

SELL
$8.87 - $12.94 $102,501 - $149,534
-11,556 Reduced 24.24%
36,112 $367,000
Q4 2021

Jun 21, 2023

SELL
$8.87 - $12.94 $177,506 - $258,955
-20,012 Reduced 35.66%
36,112 $367,000
Q4 2021

Mar 22, 2023

SELL
$8.87 - $12.94 $177,506 - $258,955
-20,012 Reduced 35.66%
36,112 $367,000
Q4 2021

Feb 15, 2022

BUY
$8.87 - $12.94 $320,313 - $467,289
36,112 New
36,112 $368,000

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $431M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.